MedPath

Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma

Not Applicable
Not yet recruiting
Conditions
Melasma
Interventions
Other: Liftactiv® B3 Serum
Other: Liftactiv® B3 retinol night cream
Other: Sunscreen UVAage® Inter SPF 50+
Other: Mineral 89 cream
Registration Number
NCT06516224
Lead Sponsor
Cosmetique Active International
Brief Summary

This 6 month, comparative study assesses the benefit of a dermocosmetic regimen (Serum B3 + B3 retinol night cream) for 6 months compared to hydroquinone 4% (the gold standard in hyperpigmentation) followed by the dermocosmetic regimen for 3 months or the Kligman Trio for 3 months followed by the dermocosmetic regimen for 3 months in adult women with melasma on the face.

Detailed Description

Study objective

1. Assessing the antipigmenting efficacy of the routine (serum B3 + B3 retinol night cream) in women with melasma.

2. Evaluation of Kligman Trio (KT) (Vitacid Plus) compared to the routine (serum B3 + B3 retinol night cream)

3. Evaluation of Hydroquinone 4% (HQ 4%) compared to the routine (serum B3 + B3 retinol night cream).

4. Assessment of the routine maintenance with SERUM B3 + retinol B3 night cream after 3 months of use of Klingman Trio (KT)(Vitacid plus) and HQ4%

Primary endpoint:

o Improvement of mMASI and MASI

Secondary endpoints:

* Improvement of Physician Global Assessment IGA for melasma

* Improvements on clinical parameters such as fine lines, skin tone, radiance, skin texture and skin elasticity evaluated by the investigator.

* Global efficacy by the subject and by the investigator (Physician's Global assessment)

* Global tolerance

* Safety

* Cosmetic acceptability

* Improvement of Quality of life (MelasQOL)

* Exposome questionnaire

* Questionnaire on hormonal status

* Improvement of the morphological and structural characteristics of ageing skin - By confocal microscopy (15 subjects per subgroup)

* Clinical scoring: hyperpigmentation scale

* Standard facial pictures with Colorface®

* Chromameter® measurements (target lesion assessment compared to non lesional surrounding skin)

* Tewameter® measurements

* Corneometer® measurements

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
150
Inclusion Criteria
  • 18-65 years
  • Phototype II-V
  • 50% with sensitive skin (declarative);
  • Subjects should be affected by well defined symmetrical (on both sides of the face) epidermal melasma (clinically diagnosed under Wood's light examination) lasting since more than a year
Exclusion Criteria
  • Subjects under topical or systemic retinoids;
  • Subjects having used topical tretinoin within 3 months or topical hydroquinone within 6 months prior to inclusion;
  • Subjects under systemic immunosuppressants and considered immune compromised
  • Subjects under active treatment of melasma (including topicals or procedures) within the last 3 months
  • Pregnant women and/or breastfeeding women
  • Subjects with a recent change in contraception (since less than 6 months);
  • Subjects known allergy to any component of tested product;
  • Subjects not presenting with the conditions needed to comply with the protocol;
  • Subjects without any other dermatological conditions on the face
  • Subject under menopause phase with hormonal replace therapy
  • Subjects in the initial phase, change or discontinuation of hormonal treatment (estroprogesterone, cyproteron acetate, androgenic...) in the last 3 months;
  • Subjects currently using any medication, which in the opinion of the investigator, may affect the evaluation of the study product, or place the subject at undue risk.
  • Subjects unable to give their informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 1Liftactiv® B3 retinol night creamdermocosmetic regimen consisting in Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream (all Vichy Laboratoires, France) for 6 months + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+
Group 2Mineral 89 creamhydroquinone 4% (HQ4%, Hydroquinona 40 mg/g, Germed, Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
Group 3Liftactiv® B3 SerumCombination of hydroquinone, resorcinol corticosteroid (Kligman Trio, Vitacid Plus Cream, Claredor Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
Group 1Sunscreen UVAage® Inter SPF 50+dermocosmetic regimen consisting in Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream (all Vichy Laboratoires, France) for 6 months + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+
Group 1Mineral 89 creamdermocosmetic regimen consisting in Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream (all Vichy Laboratoires, France) for 6 months + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+
Group 2Liftactiv® B3 retinol night creamhydroquinone 4% (HQ4%, Hydroquinona 40 mg/g, Germed, Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
Group 2Sunscreen UVAage® Inter SPF 50+hydroquinone 4% (HQ4%, Hydroquinona 40 mg/g, Germed, Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
Group 3Sunscreen UVAage® Inter SPF 50+Combination of hydroquinone, resorcinol corticosteroid (Kligman Trio, Vitacid Plus Cream, Claredor Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
Group 1Liftactiv® B3 Serumdermocosmetic regimen consisting in Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream (all Vichy Laboratoires, France) for 6 months + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+
Group 2Liftactiv® B3 Serumhydroquinone 4% (HQ4%, Hydroquinona 40 mg/g, Germed, Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
Group 3Liftactiv® B3 retinol night creamCombination of hydroquinone, resorcinol corticosteroid (Kligman Trio, Vitacid Plus Cream, Claredor Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
Group 3Mineral 89 creamCombination of hydroquinone, resorcinol corticosteroid (Kligman Trio, Vitacid Plus Cream, Claredor Brazil) for 3 months followed by the dermocosmetic regimen (Liftactiv(® B3 serum + Liftactiv® B3 retinol night cream + Mineral 89 cream + Sunscreen UVAage Inter SPF 50+) for 3 months
Primary Outcome Measures
NameTimeMethod
antipigmenting assessmentDay 168

modified Melasma Area Severity Index (mMASI)

Secondary Outcome Measures
NameTimeMethod
antipigmenting assessmentDay 140

modified Melasma Area Severity Index (mMASI)

Investigator Global Assessment (IGA) assessmentDay 168

IGA score

Clinical assessment (fine lines, skin tone, radiance, texture and elasticity)Day 168

scores 0 to 5

Clinical scoring hyperpigmentationDay 168

scale 0 to 10

Clinical scoring target lesion comparing to surrounding skinDay 168

scale 0 to 10

imagesDay 168

Standard facial pictures with Colorface® using standard 60, cross polarized, UV and no filters lights.

Skin qualityDay 168

Chromameter, Individual Typology Angle (ITA)

confocalDay 168

confocal measurements (15 subjects)

Melasma statusbaseline

questionnaire

adverse eventsDay 168

reporting

skin hydrationDay 168

Corneometer

Subject global efficay ratingDay 168

rating

Investigator global efficay ratingDay 168

rating

Cosmetic acceptabilityDay 168

questionnaire

Evolution of quality of lifeDay 156

MelasQoL

transepidermal water lossDay 168

Tewameter

exposome questionnairebaseline

questionnaire

Trial Locations

Locations (1)

CIDP

🇧🇷

Rio de Janeiro, Brazil

© Copyright 2025. All Rights Reserved by MedPath